Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in Achalasia
NCT03411252Phase 1Terminated
- Sponsor
- Thomas Jefferson University
- Start
- Feb 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in achalasia comparing Mirabegron First with Placebo First (2 arms). Primary endpoint: Changes in lower esophageal sphincter pressures at 4 weeks. Started Feb 2018; status: terminated.
02
Drugs
mirabegron
03
Conditions
achalasia
Beyond the preview
Go deeper on NCT03411252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411252.